Novartis suspended multiple studies of a CAR T candidate after three patients who received the therapy suffered fatal cases ...

The data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution ...

Seven of the 10 companies participating in the fall cohorts of MassBio and SCbio’s Drive program are based in the United ...

With M&A rising, venture capital returning and policy risks easing, biotech is on a positive trajectory following a prolonged ...

Zanvastro, an antisense oligonucleotide therapy, represents the first independent neurology launch for Ionis Pharmaceuticals, ...

With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of ...

The U.S. is scrambling to compete with a strategically positioned China on the biotech stage as the Asian country surpasses ...

After downsizing by 50% last year, Arsenal Biosciences is again laying off employees. This time, 99 people are getting cut as ...

Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate ...

Almost as many biotechs have opted for a reverse merger to reach the public markets as those executing more traditional ...

Roche has tapped Simcere Zaiming for a new T cell engager that could have broad application in B cell–mediated diseases ...

Current leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other ...